Products & ReviewLife Sciences

therascreen KRAS RGQ PCR Kit

QIAGENAvailable: Worldwide

The  therascreen  KRAS RGQ PCR Kit is a real-time, qualitative in vitro diagnostic test for the detection of 7 somatic mutations in the  KRAS  oncogene using a sample of DNA extracted from formalin-fixed, paraffin-embedded (FPPE) non-small cell lung cancer (NSCLC) tissue and colorectal cancer (CRC) tissue.

QIAGEN

The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our  Product Directory.

Ease of Use
After Sales Service
Value for Money
Write your own review

The therascreen KRAS RGQ PCR Kit is a real-time, qualitative in vitro diagnostic test for the detection of 7 somatic mutations in the KRAS oncogene using a sample of DNA extracted from formalin-fixed, paraffin-embedded (FPPE) non-small cell lung cancer (NSCLC) tissue and colorectal cancer (CRC) tissue.

The therascreen KRAS RGQ PCR Kit is an FDA-approved companion diagnostic (CDx) PCR test intended to aid in the identification of NSCLC patients for treatment with LUMAKRAS (sotorasib) or KRAZATI (adagrasib) based on a KRAS G12C Mutation Detected result. In addition, the kit is also an FDA-approved CDx test to aid in the selection of patients with CRC who may be eligible for treatment with Erbitux (cetuximab) or Vectibix (panitumumab), based on a KRAS No Mutation Detected test result.

Product Overview

Links